A Long-term, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Flexible-Dose Brexpiprazole as Maintenance Treatment in Adolescents (13-17 Years Old) With Schizophrenia
Phase of Trial: Phase III
Latest Information Update: 25 Nov 2019
Price : $35 *
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 31 Jul 2019 Planned End Date changed from 1 Dec 2022 to 1 Nov 2023.
- 31 Jul 2019 Planned primary completion date changed from 1 Dec 2022 to 1 Nov 2023.
- 31 Aug 2018 Biomarkers information updated